Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 16/20 | 0.55 |
| ▸ | MAPK13 | O15264 | 15/20 | 0.55 |
| ▸ | MAPK12 | P53778 | 15/20 | 0.55 |
| ▸ | MAPK11 | Q15759 | 15/20 | 0.55 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6767908 | 0.93 | MAPK14 (0.53) | MAPK14MAPK13MAPK12MAPK11MKNK1 | |
| SCHEMBL6766809 | 0.93 | MAPK14 (0.64) | MAPK14MAPK13MAPK12MAPK11MKNK1 | |
| SCHEMBL6773237 | 0.92 | MAPK14 (0.57) | MAPK14MAPK13MAPK12MAPK11MKNK1 | |
| SCHEMBL6766841 | 0.88 | MAPK14 (0.53) | MAPK14MAPK13MAPK12MAPK11MKNK1 | |
| SCHEMBL6768759 | 0.86 | MAPK13 (0.51) | MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL6767026 | 0.85 | MAPK13 (0.50) | MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL6764031 | 0.80 | MAPK14 (0.41) | MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL6767002 | 0.80 | MAPK14 (0.49) | MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL6768619 | 0.78 | MAPK14 (0.52) | MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL6773236 | 0.76 | MAPK13 (0.45) | MAPK14MAPK13MAPK12MAPK11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6677337-B2 | RHEUMATOID ARTHRITIS, OSTEOARTHRITIS, INFLAMMATORY BOWEL DISEASE, CACHEXIA, SEPTIC SHOCK, CARDIOVASCULAR AND RESPIRATORY SYSTEM DISORDERS | THE PROCTER & GAMBLE COMPANY | 2004-01-13 | — | — | US | claimed |
| US-20030225082-A1 | 1,2-dihydropyrazol-3-ones which controls inflammatory cytokines | PROCTER & GAMBLE COMPANY, THE | 2003-12-04 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225082-A1 | 1,2-dihydropyrazol-3-ones which controls inflammatory cytokines | IL1B, IL1A, IL1R1 | MAPK14 1086/4885MAPK13 1053/4885MAPK12 997/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.